ifx-1
mAbexperimentalCOVID-19
Clinical trial activity
13 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
11
Phase 3
2
Phase 4
0
Earliest trial started Mar 1, 2011 (NCT01319903)
Timeline
Indications
Studied for
- COVID-19 · Phase 2/Phase 3
- General Surgery · Phase 2
- Granuloma · Phase 2
- Hidradenitis Suppurativa · Phase 2
- Microscopic Polyangiitis · Phase 2
- Pharmacological and Toxicological Phenomena · Phase 1
- Pyoderma Gangrenosum · Phase 3
- Respiratory Distress Syndrome · Phase 2
- Sclerosis · Phase 2
- Sepsis · Phase 2
- Severe Acute Respiratory Syndrome · Phase 2
- Shock, Septic · Phase 2
- Skin Neoplasms · Phase 2
- Systemic Inflammatory Response Syndrome · Phase 2
Mechanism of action
- Complement C5INHIBITOR
C5 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109636 ↗
Also known as
- cacp29
- cacp29
- ifx-1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06701682 | Phase 2 | Dec 27, 2024 | Department of Health and Human Services, Edesa Biotech Inc., Genentech, InflaRx GmbH, PPD |
| NCT06703073 | Phase 2 | Dec 20, 2024 | Department of Health and Human Services, Edesa Biotech Inc., Genentech, InflaRx GmbH, PPD |
| NCT05964413 | Phase 3 | Aug 15, 2023 | InflaRx GmbH |
| NCT04812535 | Phase 2 | Jun 1, 2021 | InflaRx GmbH, University of Duisburg-Essen |
| NCT04333420 | Phase 2/Phase 3 (Phase 3) | Mar 31, 2020 | InflaRx GmbH, University of Amsterdam |
| NCT03971643 | Phase 2 | May 31, 2019 | InflaRx GmbH, Innovaderm |
| NCT03895801 | Phase 2 | Mar 22, 2019 | InflaRx GmbH, IQVIA |
| NCT03712345 | Phase 2 | Oct 15, 2018 | InflaRx GmbH, IQVIA, University of Pennsylvania |
| NCT03487276 | Phase 2 | Feb 26, 2018 | InflaRx GmbH, IQVIA |
| NCT03001622 | Phase 2 | Dec 1, 2016 | InflaRx GmbH |
| NCT02866825 | Phase 2 | May 1, 2016 | Friedrich Schiller University, InflaRx GmbH |
| NCT02246595 | Phase 2 | Apr 1, 2014 | Friedrich Schiller University, InflaRx GmbH |
| NCT01319903 | Phase 1 | Mar 1, 2011 | InflaRx GmbH, Nuvisan Pharma Services |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| InflaRx GmbH | For profit | 13 | 11 | 3 | 2011 |
| IQVIA | For profit | 3 | 0 | 1 | 2018 |
| Department of Health and Human Services | Government | 2 | 0 | 1 | 2024 |
| Edesa Biotech Inc. | For profit | 2 | 0 | 1 | 2024 |
| Friedrich Schiller University | Academic/Hospital | 2 | 0 | 1 | 2014 |
| Genentech | For profit | 2 | 0 | 1 | 2024 |
| PPD | For profit | 2 | 2 | 1 | 2024 |
| Innovaderm | For profit | 1 | 0 | 1 | 2019 |
| Nuvisan Pharma Services | For profit | 1 | 0 | 1 | 2011 |
| University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Duisburg-Essen | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2018 |
12 organizations
Page 1 / 1